Among the many clinical concerns in the context of cancer, chronic hypoxia is one of them, and the prospect of HIF-2-directed therapeutics is now feasible, judging by recent findings that identify a key HIF-2 target gene, namely, tubulin beta-3 chain (TUBB3), which is involved in tumor advancement and chemotherapy [109]. This evidence concerns the gene TUBB3 and neoplasm.